JP2001508302A - 胚性幹細胞血清置換 - Google Patents
胚性幹細胞血清置換Info
- Publication number
- JP2001508302A JP2001508302A JP53115898A JP53115898A JP2001508302A JP 2001508302 A JP2001508302 A JP 2001508302A JP 53115898 A JP53115898 A JP 53115898A JP 53115898 A JP53115898 A JP 53115898A JP 2001508302 A JP2001508302 A JP 2001508302A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- embryonic stem
- salt
- free
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000001671 embryonic stem cell Anatomy 0.000 title claims abstract description 97
- 210000002966 serum Anatomy 0.000 title claims description 43
- 239000013589 supplement Substances 0.000 claims abstract description 186
- 239000002609 medium Substances 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 117
- 241001465754 Metazoa Species 0.000 claims abstract description 61
- 238000012258 culturing Methods 0.000 claims abstract description 46
- 230000009261 transgenic effect Effects 0.000 claims abstract description 40
- 230000012010 growth Effects 0.000 claims abstract description 30
- 239000007640 basal medium Substances 0.000 claims abstract description 25
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 430
- 239000006143 cell culture medium Substances 0.000 claims description 81
- 150000003839 salts Chemical class 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 66
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 52
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 50
- 238000009472 formulation Methods 0.000 claims description 44
- 230000004069 differentiation Effects 0.000 claims description 38
- 102000004877 Insulin Human genes 0.000 claims description 36
- 108090001061 Insulin Proteins 0.000 claims description 36
- 150000007523 nucleic acids Chemical class 0.000 claims description 34
- 108020004707 nucleic acids Proteins 0.000 claims description 34
- 102000039446 nucleic acids Human genes 0.000 claims description 34
- 210000002459 blastocyst Anatomy 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000009027 Albumins Human genes 0.000 claims description 26
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 26
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims description 26
- 239000012581 transferrin Substances 0.000 claims description 26
- 108010088751 Albumins Proteins 0.000 claims description 25
- 102000004338 Transferrin Human genes 0.000 claims description 25
- 108090000901 Transferrin Proteins 0.000 claims description 25
- 229940125396 insulin Drugs 0.000 claims description 25
- 239000012679 serum free medium Substances 0.000 claims description 24
- 239000011573 trace mineral Substances 0.000 claims description 24
- 235000013619 trace mineral Nutrition 0.000 claims description 24
- 238000004113 cell culture Methods 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 21
- 235000018102 proteins Nutrition 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 230000024245 cell differentiation Effects 0.000 claims description 19
- 241000283690 Bos taurus Species 0.000 claims description 18
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims description 17
- 239000001963 growth medium Substances 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims description 16
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 15
- 241000282693 Cercopithecidae Species 0.000 claims description 14
- 239000002243 precursor Substances 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical group OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- 230000001737 promoting effect Effects 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 210000002257 embryonic structure Anatomy 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 241000283707 Capra Species 0.000 claims description 9
- 229930182821 L-proline Natural products 0.000 claims description 9
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 9
- 239000013522 chelant Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 229960002429 proline Drugs 0.000 claims description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 241000282326 Felis catus Species 0.000 claims description 8
- 108010024636 Glutathione Proteins 0.000 claims description 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 8
- 229930182816 L-glutamine Natural products 0.000 claims description 8
- -1 L-methyl Onin Chemical compound 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 239000004026 insulin derivative Substances 0.000 claims description 8
- NCCSSGKUIKYAJD-UHFFFAOYSA-N rubidium(1+) Chemical compound [Rb+] NCCSSGKUIKYAJD-UHFFFAOYSA-N 0.000 claims description 8
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims description 8
- 241000282472 Canis lupus familiaris Species 0.000 claims description 7
- 241000699800 Cricetinae Species 0.000 claims description 7
- 241000283086 Equidae Species 0.000 claims description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 7
- 241000699670 Mus sp. Species 0.000 claims description 7
- 241000700159 Rattus Species 0.000 claims description 7
- 230000008093 supporting effect Effects 0.000 claims description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 7
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 241000271566 Aves Species 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical group [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 230000001502 supplementing effect Effects 0.000 claims description 6
- 229960004441 tyrosine Drugs 0.000 claims description 6
- 229960004295 valine Drugs 0.000 claims description 6
- 241000938605 Crocodylia Species 0.000 claims description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 102000002070 Transferrins Human genes 0.000 claims description 5
- 108010015865 Transferrins Proteins 0.000 claims description 5
- 210000000270 basal cell Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- 229960002898 threonine Drugs 0.000 claims description 5
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 241000282887 Suidae Species 0.000 claims description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 229960001153 serine Drugs 0.000 claims description 4
- 229960003495 thiamine Drugs 0.000 claims description 4
- 235000019157 thiamine Nutrition 0.000 claims description 4
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011721 thiamine Substances 0.000 claims description 4
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- 241000700198 Cavia Species 0.000 claims description 3
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 229960005261 aspartic acid Drugs 0.000 claims description 3
- 229960002413 ferric citrate Drugs 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 102000004140 Oncostatin M Human genes 0.000 claims description 2
- 108090000630 Oncostatin M Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000012592 cell culture supplement Substances 0.000 claims description 2
- 102000013361 fetuin Human genes 0.000 claims description 2
- 108060002885 fetuin Proteins 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 229960002989 glutamic acid Drugs 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 230000001817 pituitary effect Effects 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 229940102001 zinc bromide Drugs 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 8
- 150000004687 hexahydrates Chemical class 0.000 claims 6
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims 3
- 150000004685 tetrahydrates Chemical class 0.000 claims 3
- 101710134784 Agnoprotein Proteins 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 2
- 229960005190 phenylalanine Drugs 0.000 claims 2
- 229960001471 sodium selenite Drugs 0.000 claims 2
- 235000015921 sodium selenite Nutrition 0.000 claims 2
- 239000011781 sodium selenite Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- ANTRPKFJBXHKNT-UHFFFAOYSA-N zinc sulfide heptahydrate Chemical compound O.O.O.O.O.O.O.[S--].[Zn++] ANTRPKFJBXHKNT-UHFFFAOYSA-N 0.000 claims 2
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 235000013878 L-cysteine Nutrition 0.000 claims 1
- 239000004201 L-cysteine Substances 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 102000015215 Stem Cell Factor Human genes 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 238000009640 blood culture Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004240 ciliary body Anatomy 0.000 claims 1
- GSQKXUNYYCYYKT-UHFFFAOYSA-N cyclo-trialuminium Chemical compound [Al]1[Al]=[Al]1 GSQKXUNYYCYYKT-UHFFFAOYSA-N 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- 229960002743 glutamine Drugs 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 239000012913 medium supplement Substances 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 150000004689 octahydrates Chemical class 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 235000018716 sodium selenate Nutrition 0.000 claims 1
- 239000011655 sodium selenate Substances 0.000 claims 1
- 229960001881 sodium selenate Drugs 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 35
- 239000012091 fetal bovine serum Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 229940050528 albumin Drugs 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 13
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- 210000004602 germ cell Anatomy 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000002242 embryoid body Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000010363 gene targeting Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000007747 plating Methods 0.000 description 6
- 239000004017 serum-free culture medium Substances 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000000472 morula Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 102000006822 Agouti Signaling Protein Human genes 0.000 description 3
- 108010072151 Agouti Signaling Protein Proteins 0.000 description 3
- 241000484025 Cuniculus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000012092 media component Substances 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000001608 teratocarcinoma Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012577 media supplement Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000012090 serum-supplement Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 238000011714 129 mouse Methods 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004703 blastocyst inner cell mass Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960001425 deferoxamine mesylate Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical class NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000008771 sex reversal Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical group [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0043—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.アルブミンまたはアルブミン置換物、1つ以上のアミノ酸、1つ以上のビタ ミン、1つ以上のトランスフェリンまたはトランスフェリン置換物、1つ以上の 抗酸化剤、1つ以上のインスリンまたはインスリン置換物、1つ以上のコラーゲ ン前駆体、および1つ以上の微量元素からなる群から選択される1つ以上の成分 を含む無血清真核生物細胞培養培地補充物であって、ここで該補充物で補充され た基本細胞培養培地が、胚性幹細胞の無血清培養中での増殖を支持し得る、無血 清真核生物細胞培養培地補充物。 2.アルブミンまたはアルブミン置換物、ならびに1つ以上のアミノ酸、1つ以 上のビタミン、1つ以上のトランスフェリンまたはトランスフェリン置換物、1 つ以上の抗酸化剤、1つ以上のインスリンまたはインスリン置換物、1つ以上の コラーゲン前駆体、および1つ以上の微量元素からなる群から選択される1つ以 上の成分を含む無血清真核生物細胞培養培地補充物であって、ここで該補充物で 補充された基本細胞培養培地が、胚性幹細胞の無血清培養中での増殖を支持し得 る、無血清真核生物細胞培養培地補充物。 3.前記抗酸化剤が、還元グルタチオンおよびアスコルビン酸アスコルビン酸-2 −ホスフェートからなる群から選択される、請求項1に記載の無血清真核生物細 胞培養培地補充物。 4.前記コラーゲン前駆体が、L-プロリンおよびその多量体または誘導体、L-ヒ ドロキシプロリン多量体またはその誘導体、ならびにアスコルビン酸およびその 多量体からなる群から選択される、請求項1に記載の無血清真核生物細胞培養培 地補充物。 5.前記トランスフェリン置換物が、クエン酸第二鉄キレートおよび硫酸第一鉄 キレートからなる群から選択される鉄キレートである、請求項1に記載の無血清 真核生物細胞培養培地補充物。 6.前記トランスフェリン置換物が、硫酸第一鉄七水和物EDTAである、請求項5 に記載の無血清真核生物細胞培養培地補充物。 7.前記インスリン置換物が、塩化亜鉛、臭化亜鉛、および硫化亜鉛七水和物か らなる群から選択される、請求項1に記載の無血清真核生物細胞培養培地補充物 。 8.前記インスリン置換物が、硫化亜鉛七水和物である、請求項7に記載の無血 清真核生物細胞培養培地補充物。 9.前記アミノ酸成分が、グリシン、L-アラニン、L-アスパラギン、L-システイ ン、L-アスパラギン酸、L-グルタミン酸、L-フェニルアラニン、L-ヒスチジン、 L-イソロイシン、L-リジン、L-ロイシン、L-グルタミン、L-アルギニン、L-メチ オニン、L-プロリン、L-ヒドロキシプロリン、L-セリン、L-スレオニン、L-トリ プトファン、L-チロシン、およびL-バリン、ならびにそれらの誘導体からなる群 から選択される1つ以上のアミノ酸を含む、請求項1に記載の無血清真核生物細 胞培養培地補充物。 10.前記アルブミン置換物が、ウシ下垂体抽出物、植物加水分解物、ウシ胎仔 アルブミン(フェチュイン)、卵アルブミン、ヒト血清アルブミン(HSA)、ニ 選択される、請求項1に記載の無血清真核生物細胞培養培地補充物。 核生物細胞培養培地補充物。 12.前記微量元素成分が、Ag+、Al3+、Ba2+、Cd2+、Co2+、Cr3+、Ge4+、Se4+ 、Br-、I-、Mn2+、F-、Si4+、V5+、Mo6+、Ni2+、Rb+、Sn2+、およびZr4+からな る群から選択さ れる1つ以上の微量元素部分を含む、請求項1に記載の無血清真核生物細胞培養 培地補充物。 13.前記補充物が濃縮される、請求項1に記載の無血清真核生物細胞培養培地 補充物。 14.前記補充物が、約2倍〜約10倍濃縮される、請求項1に記載の無血清真核 生物細胞培養培地補充物。 15.前記補充物が、約0.5%〜約90%の最終濃度まで基本培地に添加される、 請求項1に記載の無血清真核生物細胞培養培地補充物。 16.前記補充物が、約5%〜約50%の最終濃度まで基本培地に添加される、請 求項15に記載の無血清真核生物細胞培養培地補充物。 17.前記補充物が、約5%〜約30%の最終濃度まで基本培地に添加される、請 求項16に記載の無血清真核生物細胞培養培地補充物。 18.前記補充物が、約5%〜約20%の最終濃度まで基本培地に添加される、請 求項17に記載の無血清真核生物細胞培養培地補充物。 19.前記補充物が、約15%の最終濃度まで基本培地に添加される、請求項18 に記載の無血清真核生物細胞培養培地補充物。 20.アルブミンまたはアルブミン置換物と、1つ以上のアミノ酸、1つ以上の ビタミン、1つ以上のトランスフェリンまたはトランスフェリン置換物、1つ以 上の抗酸化剤、1つ以上のインスリンまたはインスリン置換物、1つ以上のコラ ーゲン前駆体、および1つ以上の微量元素からなる群から選択される1つ以上の 成分とを組み合わせることによって得られる無血清真核生物細胞培養培地補充物 であって、 ここで該補充物で補充された基本細胞培養培地が、無血清培養において胚性幹 細胞の増殖を支持し得る、無血清真核生物細胞培養培地補充物。 -フェニルアラニン、L-プロリン、L-ヒドロキシプロリン、L-セリン、L-スレオ ニン、L-トリプトファン、L-チロシン、L-バリン、チアミン、還元グルタチオン 、L-アスコルビン酸-2−ホスフェート、鉄飽和トランスフェリン、インスリン、 亜セレン酸ナトリウム、Ag+、Al3+、Ba2+、Cd2+、Co2+、Cr3+、Ge4+、Se4+、Br- 、I-、Mn2+、F-、Si4+、V5+、Mo6+、Ni2+、Rb+、Sn2+、およびZr4+を含む無血清 真核生物細胞培養培地補充物であって、 ここで該補充物で補充された基本細胞培養培地が、無血清培養において胚性幹 細胞の増殖を支持し得る、無血清真核生物細胞培養培地補充物。 メチオニン、L-フェニルアラニン、L-プロリン、L-ヒドロキシプロリン、L-セリ ン、L-スレオニン、L-トリプトファン、L-チロシン、L-バリン、チアミン、還元 グルタチオン、L-アスコルビン酸-2−ホスフェート、鉄飽和トランスフェリン、 インスリン、亜セレン酸ナトリウム、Ag+塩、Al3+塩、Ba2+塩、Cd2+塩、Co2+塩 、Cr3+塩、Ge4+塩、Se4+塩、Br-塩、I-塩、Mn2+塩、F-塩、Si4+塩、V5+塩、Mo6+ 塩、Ni2+塩、Rb+塩、Sn2+塩、およびZr4+塩を組み合わせることによって得られ る無血清真核生物細胞培養培地補充物であって、 ここで各成分が、基本培地に添加された場合に、無血清培養において胚性幹細 胞の増殖を支持する量で存在する、無血清真核生物細胞培養培地補充物。 23.前記Ag+塩がAgNO3であり、前記Al3+塩がAlCl3六水和物であり、前記Ba2+ 塩がBa(C2H3O2)2であり、前記Cd2+塩がCdSO4八水和物であり、前記Co2+塩がCoCl2 六水和物であり、前記Cr3+塩がCr2(SO4)3一水和物であり、前記Ge4+塩がGeO2で あり、前記Se4+塩がNa2SeO3およびH2SeO3であり、前記Br-塩がKBrであり、前記I- 塩がKIであり、 前記Mn2+塩がMnCl2四水和物であり、前記F-塩がNaFであり、前記Si4+塩がNa2SiO3 九水和物、前記V5+塩がNaVO3であり、前記Mo6+塩が(NH4)6MO7O24四水和物であ り、前記Ni2+塩がNiSO4六水和物であり、前記Rb+塩がRbClであり、前記Sn2+塩が SnCl2であり、そして前記Zr4+塩がZrOCl2八水和物である、請求項22に記載の 無血清真核生物細胞培養培地補充物。 24.無血清真核生物細胞培養培地補充物を作製する方法であって、該方法は、 フェニルアラニン、L-プロリン、L-ヒドロキシプロリン、L-七リン、L-スレオニ ン、L-トリプトファン、L-チロシン、L-バリン、チアミン、還元グルタチオン、 L-アスコルビン酸-2−ホスフェート、鉄飽和トランスフェリン、インスリン、亜 セレン酸ナトリウム、Ag+塩、Al3+塩、Ba2+塩、Cd2+塩、Co2+塩、Cr3+塩、Ge4+ 塩、Se4+塩、Br-塩、I-塩、Mn2+塩、F-塩、Si4+塩、V5+塩、Mo6+塩、Ni2+塩、Rb+ 塩、Sn2+塩、およびZr4+塩を混合する工程を包含し、 ここで各成分が、基本培地に添加された場合に、無血清培養において胚性幹細 胞の増殖を支持する量で存在する、方法 25.前記Ag+塩がAgNO3であり、前記Al3+塩がAlCl3六水和物であり、前記Ba2+ 塩がBa(C2H3O2)2であり、前記Cd2+塩がCdSO4八水和物であり、前記Co2+塩がCoCl2 六水和物であり、前記Cr3+塩がCr2(SO4)3一水和物であり、前記Ge4+塩がGeO2で あり、前記Se4+塩がNa2SeO3およびH2SeO3であり、前記Br-塩がKBrであり、前記I- 塩がKIであり、前記Mn2+塩がMnCl2四水和物であり、前記F-塩がNaFであり、前 記Si4+塩がNa2SiO3九水和物、前記V5+塩がNaVO3であり、前記Mo6+塩が(NH4)6Mo7 O24四水和物であり、前記Ni2+塩がNiSO4六水和物であり、前記Rb+塩がRbClであ り、前記Sn2+塩がSnCl2であり、そして前記Zr4+塩がZrOCl2八水和物である、請 求項23に記載の方法。 26.請求項1に記載の無血清細胞培養補充物を補充した基本細胞培養培地を含 む無血清真核生物細胞培養培地であって、 ここで該補充された培養培地が、無血清培養において胚性幹細胞の増殖を支持 し得る、無血清真核生物細胞培養培地。 27.前記培地が、1×培地処方物である、請求項26に記載の無血清真核生物 細胞培養培地。 28.前記培地が濃縮された培地処方物である、請求項26に記載の無血清真核 生物細胞培養培地。 29.前記補充物の最終濃度が、約0.5%〜約90%である、請求項26に記載の 無血清真核生物細胞培養培地。 30.前記補充物の最終濃度が、約5%〜約50%である、請求項29に記載の無 血清真核生物細胞培養培地。 31.前記補充物の最終濃度が、約5%〜約30%である、請求項30に記載の無 血清真核生物細胞培養培地。 32.前記補充物の最終濃度が、約5%〜約20%である、請求項31に記載の無 血清真核生物細胞培養培地。 33.前記補充物の最終濃度が、約15%である、請求項30に記載の無血清真核 生物細胞培養培地。 34.基本細胞培養培地と、請求項1に記載の無血清補充物とを組み合わせるこ とによって得られる無血清真核生物細胞培養培地であって、 ここで該培地が、無血清培養において胚性幹細胞の増殖を支持し得る、無血清 真核生物細胞培養培地。 35.無血清真核生物細胞培養培地を作製する方法であって、該方法は、基本細 胞培養培地と、請求項1に記載の補充物とを混合する工程を包含し、 ここで該培地が、無血清培養において胚性幹細胞の増殖を支持し得る、方法。 36.前記培地が1×処方物である、請求項35に記載の方法。 37.前記培地が濃縮された処方物である、請求項35に記載の方法。 38.前記補充物の最終濃度が、約0.5%〜約90%である、請求項35に記載の 方法による無血清真核生物細胞培養培地。 39.前記補充物の最終濃度が、約5%〜約50%である、請求項38に記載の方 法による無血清真核生物細胞培養培地。 40.前記補充物の最終濃度が、約5%〜約30%である、請求項39に記載の方 法による無血清真核生物細胞培養培地。 41.前記補充物の最終濃度が、約5%〜約20%である、請求項40に記載の方 法による無血清真核生物細胞培養培地。 42.前記補充物の最終濃度が、約15%である、請求項41に記載の方法による 無血清真核生物細胞培養培地。 43.無血清培地において胚性幹細胞を含む組成物であって、該無血清培地が、 無血清培地において胚性幹細胞の増殖を支持し得る、組成物。 44.前記培地が、請求項26または34に記載の培地である、請求項43に記 載の組成物。 45.前記組成物が、約-135℃以下で無期限に保存され得る、請求項44に記載 の組成物。 46.前記胚性幹細胞が、ヒト、有尾猿、無尾猿、マウス、ラット、ハムスター 、ウサギ、モルモット、ウシ、ブタ、イヌ、ウマ、ネコ、ヤギ、ヒツジ、鳥類、 爬虫類、魚、および両生類からなる群から選択される動物から得られる、請求項 45に記載の組成物。 47.前記胚性幹細胞が、マウス、ウシ、ヤギ、およびヒツジからなる群から選 択される動物から得られる、請求項46に記載の組成物。 48.前記胚性幹細胞が、マウスから得られる、請求項47に記載の組成物。 49.胚性幹細胞および請求項1に記載の補充物を含む容器手段を含む、製造産 物。 50.請求項26または34に記載の培地中に胚性幹細胞を含む容器手段を含む 、製造産物。 51.1つ以上の容器手段を含む製造産物であって、ここで、第1容器手段が請 求項1に記載の補充物を含み、ここで必要に応じて、第2容器手段が基本培地を 含み、ここで必要に応じて、第3容器手段が胚性幹細胞を含む、製造産物。 52.1つ以上の容器手段を含む製造産物であって、ここで、第1容器手段が請 求項26または34に記載の培地を含み、ここで必要に応じて第2容器手段が胚 性幹細胞を含む、製造産物。 53.前記製造産物が凍結状態である、請求項49〜52のいずれか1つに記載 の製造産物。 54.無血清培養において胚性幹細胞を拡大する方法であって、 (a)該胚性幹細胞を、請求項26または34に記載の培地と接触させる工程 ;および (b)該胚性幹細胞を、該胚性幹細胞の拡大を容易にするのに適した無血清条 件下で培養する工程、 を包含する、方法。 55.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項54に記載の方法。 56.トランスジェニック動物を産生する方法であって、 (a)胚性幹細胞を、請求項26または34に記載の培地において培養する工 程; (b)核酸分子を、該胚性幹細胞に導入する工程; (c)組換え胚性幹細胞クローンを選択する工程; (d)該組換え胚性幹細胞クローンを拡大して、集団を形成する工程; (e)該組換え胚性幹細胞クローン集団のアリコートを、胚盤胞に注入する工 程; (f)該注入した胚盤胞を、宿主偽妊娠雌性動物に移す工程;および (g)トランスジェニック子孫を選択する工程、 を包含する、方法。 57.前記培養工程が、 (a1)前記胚性幹細胞を、請求項26または34に記載の培地と接触させる工 程;および (a2)該胚性幹細胞を、該胚性幹細胞の拡大を容易にするのに適した無血清条 件下で、無血清培地において培養する工程、 をさらに包含する、請求項56に記載の方法。 58.前記胚性幹細胞を、支持細胞の層上に播種する工程を包含する、請求項5 7に記載の方法。 59.トランスジェニック動物を産生する方法であって、 (a)胚性幹細胞を、請求項26または34に記載の培地において培養する工 程; (b)核酸分子を、該胚性幹細胞に導入する工程; (c)組換え胚性幹細胞クローンを選択する工程; (d)該組換え胚性細胞クローンを拡大して、集団を形成する工程; (e)少数の該胚性幹細胞を、初期胚と同時培養して、胚の凝集を形成する工 程; (f)該凝集した胚を、宿主偽妊娠雌性動物に移入する工程;および (g)トランスジェニック子孫を選択する工程、 を包含する、方法。 60.前記培養工程が、 (a1)前記胚性幹細胞を、請求項26または34に記載の培地と接触させる工 程;および (a2)該胚性幹細胞を、無血清培養において該胚性幹細胞の拡大を促進するの に適した無血清条件下で培養する工程、 をさらに包含する、請求項59に記載の方法。 61.前記胚性幹細胞を、支持細胞の層上に播種する工程を包含する、請求項6 0に記載の方法。 62.組換えタンパク質をトランスジェニック動物から産生する方法であって、 (a)胚性幹細胞を、請求項26または34に記載の培地において培養する工 程; (b)該タンパク質をコードする目的のタンパク質をコードする核酸分子を含 む核酸構築物を、該胚性幹細胞に導入する工程; (c)組換え胚性幹細胞クローンを選択する工程; (d)該組換え胚性幹細胞クローンを拡大して、組換え胚性幹細胞の集団を形 成する工程; (e)該組換え胚性幹細胞クローン集団を、胚盤胞に注入する工程; (f)該注入された胚盤胞を、宿主偽妊娠雌性動物に移入する工程; (g)トランスジェニック子孫を選択する工程; (h)該選択されたトランスジェニック動物を、該トランスジェニック動物の 健康を促進するのに適した条件下で成育させる工程;および (i)該組換えタンパク質を、該トランスジェニック動物から単離する工程、 を包含する、方法。 63.前記培養工程が、 (a1)前記胚性幹細胞を、請求項26または34に記載の培地と接触させる工 程;および (a2)前記胚性幹細胞を、無血清培養において前記胚性幹細胞の拡大を促進す るのに適した無血清条件下で培養する工程、 をさらに包含する、請求項62に記載の方法。 64.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項63に記載の方法。 65.組換えタンパク質を、トランスジェニック動物から産生する方法であって 、 (a)胚性幹細胞を、請求項26または34に記載の培地において培養する工 程; (b)該タンパク質をコードする目的のタンパク質をコードする核酸分子を含 む核酸構築物を、該胚性幹細胞に導入する工程; (c)組換え胚性幹細胞クローンを選択する工程; (d)該組換え胚性幹細胞クローンを拡大して、組換え胚性幹細胞の集団を形 成する工程; (e)少数の胚性幹細胞を、初期胚と同時培養して、胚の凝集を形成する工程 ; (f)該注入された胚盤胞を、宿主偽妊娠雌性動物に移入する工程; (g)トランスジェニック子孫を選択する工程; (h)該選択されたトランスジェニック動物を、該トランスジェニック動物の 健康を促進するのに適した条件下で成育させる工程;および (i)該組換えタンパク質を、該トランスジェニック動物から単離する工程、 を包含する、方法。 66.前記方法が、 (a1)前記胚性幹細胞を、請求項26または34に記載の培地と接触させる工 程;および (a2)前記胚性幹細胞を、無血清培養において前記胚性幹細胞の拡大を促進す るのに適した条件下で培養する工程、 をさらに包含する、請求項67に記載の方法。 67.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項66に記載の方法。 68.無血清培養において、胚性幹細胞の分化を制御または予防するための方法 であって、 (a)該胚性幹細胞を、請求項26または34に記載の培地と接触させる工程 ;および (b)胚性幹細胞の分化を制御または予防し、そして無血清培養において該胚 性幹細胞の拡大を促進するのに適した無血清条件下で、該胚性幹細胞を培養する 、工程、 を包含する、方法。 69.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項68に記載の方法。 70.前記培養工程が、前記胚性幹細胞の分化を制御または予防する1つ以上の 因子を前記培地に補充することをさらに包含する、請求項69に記載の方法。 71.前記因子が、白血病抑制因子、幹細胞刺激因子(steel factor)、毛様体神 経栄養因子、およびオンコスタチンMからなる群から選択される、請求項70に 記載の方法。 72.前記因子が白血病抑制因子である、請求項71に記載の方法。 73.前記因子が幹細胞刺激因子である、請求項71に記載の方法。 74.前記因子が毛様体神経栄養因子である、請求項71に記載の方法。 75.前記因子がオンコスタチンMである、請求項71に記載の方法。 76.胚性幹細胞の無血清培地中での特定の型の細胞への分化を引き起こす方法 であって、 (a)胚性幹細胞を、請求項26または34に記載の培地に接触させる工程; (b)胚性幹細胞を、無血清培養において該胚性幹細胞の拡大を促進するのに 適した条件下で培養する工程;および (c)分化因子を添加するか、または培養条件を変更して、胚性幹細胞の分化 を誘導して、異なる型の細胞を形成する工程、 を包含する、方法。 77.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項76に記載の方法。 78.前記細胞の分化を予防し、そして前記細胞の拡大を促進するのに適した条 件下で、前記胚性幹細胞を培養する工程が、前記胚性幹細胞の分化を予防する1 つ以上の増殖因子を前記培養培地に補充することをさらに包含する、請求項76 に記載の方法。 79.前記拡大された胚性幹細胞を培養する工程が、前記胚性幹細胞の分化を促 進する1つ以上の増殖因子を前記培養培地に補充する工程をさらに包含する、請 求項76に記載の方法。 80.無血清培養において、分化した胚性幹細胞を哺乳動物に提供する方法であ って、 (a)胚性幹細胞を、請求項26または34に記載の培地に接触させる工程; (b)胚性幹細胞を、無血清培養において該胚性幹細胞の拡大を促進するのに 適した条件下で培養する工程; (c)分化因子を添加するか、または培養条件を変更して、胚性幹細胞の分化 を誘導して、異なる型の細胞を形成する工程;および (d)該分化した細胞を、哺乳動物に導入する工程、 を包含する、方法。 81.前記胚性幹細胞を、支持細胞の層上に播種する工程をさらに包含する、請 求項80に記載の方法。 82.前記胚性幹細胞を、該細胞の分化を予防するのに適した無血清条件下で培 養する工程が、1つ以上の因子を前記培養培地に補充することをさらに包含する 、請求項80に記載の方法。 83.前記因子が白血病抑制因子である、請求項82に記載の方法。 84.前記細胞の分化を誘導するのに適した条件下で、前記拡大した胚性幹細胞 を培養する工程が、1つ以上の増殖因子を前記培養培地に補充することをさらに 包含する、請求項80に記載の方法。 85.無血清培養において胚性幹細胞を得る方法であって、 (a)胚性幹細胞を、胚盤胞から単離する工程;および (b)該単離された胚性幹細胞を、請求項26または34に記載の培地におい て培養する工程、 を包含する、方法。 86.無血清培養において、組換えタンパク質胚性幹細胞を産生する方法であっ て、 (a)目的のタンパク質をコードする核酸分子を含む組換え胚性幹細胞を得る 工程; (b)無血清培養において、該胚性幹細胞を培養して、組換え胚性幹細胞の集 団を形成する工程;および (c)該タンパク質を、該胚性幹細胞、または該細胞が培養される培地から単 離する工程、 を包含する、方法。 87.前記単離工程が、 (c1)前記タンパク質を、前記胚性幹細胞から単離すること、 をさらに包含する、請求項87に記載の方法。 88.前記単離工程が、 (c1)前記タンパク質を、前記採取した培地から単離すること、 をさらに包含する、請求項86に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78177297A | 1997-01-10 | 1997-01-10 | |
US08/781,772 | 1997-01-10 | ||
PCT/US1998/000467 WO1998030679A1 (en) | 1997-01-10 | 1998-01-09 | Embryonic stem cell serum replacement |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001508302A true JP2001508302A (ja) | 2001-06-26 |
Family
ID=25123879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53115898A Ceased JP2001508302A (ja) | 1997-01-10 | 1998-01-09 | 胚性幹細胞血清置換 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20020076747A1 (ja) |
EP (1) | EP0986635A4 (ja) |
JP (1) | JP2001508302A (ja) |
AU (1) | AU5734998A (ja) |
CA (1) | CA2277278A1 (ja) |
WO (1) | WO1998030679A1 (ja) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063968A1 (ja) * | 2003-12-26 | 2005-07-14 | Gs Platz Co Ltd | Es細胞培養用基礎培地 |
WO2005078070A1 (ja) * | 2004-02-13 | 2005-08-25 | Reprocell, Inc. | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 |
CN1298843C (zh) * | 2005-02-07 | 2007-02-07 | 十堰市太和医院 | 不依赖饲养细胞的人胚干细胞培养基 |
JP2009528034A (ja) * | 2006-02-23 | 2009-08-06 | ノヴォセル インコーポレイテッド | 分化可能細胞の培養に有用な組成物及び方法 |
JP2011500024A (ja) * | 2007-10-12 | 2011-01-06 | アドバンスド セル テクノロジー, インコーポレイテッド | Rpe細胞を生成する改良された方法およびrpe細胞の組成物 |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
WO2019017492A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
WO2019054514A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
WO2019054515A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 |
WO2019103129A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
WO2019103125A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 神経系細胞又は神経組織と非神経上皮組織とを含む細胞塊の製造方法及びその細胞塊 |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
US10485829B2 (en) | 2009-11-17 | 2019-11-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
WO2019245073A1 (ko) * | 2018-06-20 | 2019-12-26 | 주식회사 디오스템스 | 항산화 조성물 |
WO2020039732A1 (ja) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 |
EP3868873A1 (en) | 2014-10-24 | 2021-08-25 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
WO2021235377A1 (ja) * | 2020-05-18 | 2021-11-25 | 株式会社マイオリッジ | 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地 |
WO2023054396A1 (ja) | 2021-09-30 | 2023-04-06 | 住友化学株式会社 | 下垂体組織を含む細胞集団の製造方法及びその細胞集団 |
WO2023054395A1 (ja) | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 |
Families Citing this family (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE399855T1 (de) * | 1996-10-10 | 2008-07-15 | Invitrogen Corp | Tierzellkulturmedium mit pflanzlichen nährstoffen |
US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
JP3880795B2 (ja) | 1997-10-23 | 2007-02-14 | ジェロン・コーポレーション | フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法 |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
US6767741B1 (en) * | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
US7455983B2 (en) | 2000-01-11 | 2008-11-25 | Geron Corporation | Medium for growing human embryonic stem cells |
US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
US7005252B1 (en) | 2000-03-09 | 2006-02-28 | Wisconsin Alumni Research Foundation | Serum free cultivation of primate embryonic stem cells |
US6458589B1 (en) | 2000-04-27 | 2002-10-01 | Geron Corporation | Hepatocyte lineage cells derived from pluripotent stem cells |
US7250294B2 (en) | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
US7112437B2 (en) | 2000-06-20 | 2006-09-26 | Es Cell International Pte Ltd. | Methods of culturing embryonic stem cells and controlled differentiation |
AU6570401A (en) * | 2000-06-20 | 2002-01-02 | Univ Monash | Method of controlling differentiation of embryonic stem (es) cells by culturing es cells in the presence of bmp-2 pathway antagonists |
JP2004504834A (ja) | 2000-08-01 | 2004-02-19 | イスム リサーチ ディベロップメント カンパニー | 胚性細胞の定方向分化 |
US7575939B2 (en) | 2000-10-30 | 2009-08-18 | Sru Biosystems, Inc. | Optical detection of label-free biomolecular interactions using microreplicated plastic sensor elements |
US7118710B2 (en) * | 2000-10-30 | 2006-10-10 | Sru Biosystems, Inc. | Label-free high-throughput optical technique for detecting biomolecular interactions |
JP4317337B2 (ja) * | 2001-10-16 | 2009-08-19 | 株式会社リプロセル | 細胞株継代用酵素溶液、および、それを用いた霊長類胚性幹細胞の培養増殖方法 |
KR20130072272A (ko) | 2001-12-07 | 2013-07-01 | 제론 코포레이션 | 인간 배아 줄기세포 유래의 조혈세포 |
IL162131A0 (en) | 2001-12-07 | 2005-11-20 | Geron Corp | Islet cells from human embryonic stem cells |
US7285415B2 (en) | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
US7927822B2 (en) | 2002-09-09 | 2011-04-19 | Sru Biosystems, Inc. | Methods for screening cells and antibodies |
FR2846004B1 (fr) * | 2002-10-16 | 2006-06-23 | Maco Pharma Sa | Composition pour culture de cellules notamment animales ou de tissus, comprenant du polyethylene glycol |
CN100549163C (zh) | 2002-12-16 | 2009-10-14 | 技术研究及发展基金有限公司 | 制备无饲养细胞、无异源的人胚胎干细胞的方法以及使用该方法制备的干细胞培养物 |
GB0304918D0 (en) * | 2003-03-05 | 2003-04-09 | Celltran Ltd | Cell culture |
WO2006019366A1 (en) * | 2003-03-28 | 2006-02-23 | Wisconsin Alumni Research Foundation | Physiochemical culture conditions for embryonic stem cells |
US7820439B2 (en) | 2003-09-03 | 2010-10-26 | Reliance Life Sciences Pvt Ltd. | In vitro generation of GABAergic neurons from pluripotent stem cells |
WO2005049812A1 (en) * | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
US20060030042A1 (en) * | 2003-12-19 | 2006-02-09 | Ali Brivanlou | Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime |
US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
WO2007059007A2 (en) | 2005-11-14 | 2007-05-24 | Cythera, Inc. | Markers of definitive endoderm |
US7510876B2 (en) | 2003-12-23 | 2009-03-31 | Cythera, Inc. | Definitive endoderm |
US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
US20050233446A1 (en) * | 2003-12-31 | 2005-10-20 | Parsons Xuejun H | Defined media for stem cell culture |
US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
WO2005070011A2 (en) | 2004-01-23 | 2005-08-04 | Advanced Cell Technology, Inc. | Improved modalities for the treatment of degenerative diseases of the retina |
KR101386690B1 (ko) * | 2004-03-04 | 2014-04-22 | 도쿠리츠교세이호진 고쿠리츠간켄큐센터 | 래트 배아 줄기 세포 |
US20080038820A1 (en) * | 2004-06-22 | 2008-02-14 | Rudy-Reil Diane E | Induction of pluripotent stem cells into mesodermal lineages |
WO2006005360A1 (en) * | 2004-07-12 | 2006-01-19 | Sorin Group Italia S.R.L. | Devices and methods for growing human cells |
GB2431165B (en) | 2004-07-13 | 2009-04-01 | Geron Corp | Medium for growing human embryonic stem cells |
CA2971062C (en) | 2004-08-16 | 2019-02-26 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
WO2006070370A2 (en) | 2004-12-29 | 2006-07-06 | Hadasit Medical Research Services & Development Limited | Stem cells culture systems |
US8597947B2 (en) | 2004-12-29 | 2013-12-03 | Hadasit Medical Research Services & Development Limited | Undifferentiated stem cell culture systems |
EP1893756B1 (en) | 2005-06-08 | 2015-08-12 | The Regents of The University of California | Elimination of n-glycolylneuraminic acid from mammalian products for human use |
GB2441488C (en) | 2005-06-22 | 2011-10-05 | Geron Corp | Suspension culture of human embryonic stem cells |
AU2006262329B2 (en) | 2005-06-22 | 2011-04-07 | Asterias Biotherapeutics, Inc. | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
EP1896568A4 (en) * | 2005-06-28 | 2009-04-29 | Ventria Bioscience | COMPONENTS OF CELL CULTURE MEDIA MANUFACTURED FROM PLANT CELLS |
FI20055398A0 (fi) | 2005-07-08 | 2005-07-08 | Suomen Punainen Risti Veripalv | Menetelmä solupopulaatioiden evaluoimiseksi |
EP1962719A4 (en) | 2005-08-29 | 2011-05-04 | Technion Res And Dev Of Foundation Ltd | MEDIA FOR BREEDING STEM CELLS |
CN103555655B (zh) | 2005-10-21 | 2018-02-27 | 细胞研究私人有限公司 | 自脐带羊膜分离和培养干/祖细胞及其分化的细胞的应用 |
JP5404047B2 (ja) | 2005-10-27 | 2014-01-29 | ヴィアサイト,インコーポレイテッド | Pdx1発現背側及び腹側前腸内胚葉 |
WO2007079533A1 (en) * | 2006-01-10 | 2007-07-19 | South Eastern Sydney And Illawarra Area Health Service | Method for establishing and proliferating human esc by co-culturing with allogeneic feeder cells in serum-free media |
US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
DK2650359T3 (da) | 2006-03-02 | 2022-06-13 | Viacyte Inc | Endokrine prekursorceller, pancreatiske hormon-udtrykkende celler og fremstillingsfremgangsmåder |
US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
EP2422800A3 (en) | 2006-03-07 | 2013-03-06 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
GB0613756D0 (en) * | 2006-07-12 | 2006-08-23 | Univ Sheffield | Cell culture medium |
EP2128244A4 (en) | 2007-01-18 | 2012-05-09 | Riken | INDUCTION / DIFFERENTIATION METHOD IN PHOTORECEPTOR CELL |
US7951593B2 (en) * | 2007-03-20 | 2011-05-31 | Universite Rene Descartes-Paris V | Culture medium for gingival fibroblasts |
US20100291042A1 (en) | 2007-05-03 | 2010-11-18 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
US9134307B2 (en) | 2007-07-11 | 2015-09-15 | X-Body, Inc. | Method for determining ion channel modulating properties of a test reagent |
NZ582473A (en) | 2007-07-11 | 2011-12-22 | Sru Biosystems Inc | Methods of identifying modulators of ion channels using a colorimetric resonant reflectance optical biosensor |
RU2473685C2 (ru) | 2007-07-31 | 2013-01-27 | Лайфскен, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
EP2190976A4 (en) * | 2007-08-10 | 2010-10-20 | Univ Dayton | METHOD FOR PRODUCING PLURIPOTENTAL STEM CELL LENGTH CELLS |
US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
JP5734836B2 (ja) | 2008-03-27 | 2015-06-17 | アステリアス バイオセラピューティクス インコーポレイテッド | 霊長類多能性幹細胞の造血系統細胞への分化 |
US20110117645A1 (en) * | 2008-03-31 | 2011-05-19 | Oriental Yeast Co., Ltd. | Method for proliferation of pluripotent stem cells |
EP2314671B1 (en) | 2008-06-06 | 2022-08-03 | Riken | Method for culture of stem cell |
KR101829310B1 (ko) | 2008-06-30 | 2018-02-14 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
CN105349517B (zh) | 2008-11-14 | 2021-05-04 | 维赛特公司 | 源于人多能干细胞的胰腺细胞的包封 |
KR20120018827A (ko) * | 2009-02-20 | 2012-03-05 | 벤트리아 바이오사이언스 | 단백질의 조합을 함유하는 세포 배양 배지 |
WO2010096746A1 (en) | 2009-02-20 | 2010-08-26 | Cellular Dynamics International, Inc. | Methods and compositions for the differentiation of stem cells |
US8372642B2 (en) * | 2009-02-27 | 2013-02-12 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
EP2233566A1 (en) | 2009-03-17 | 2010-09-29 | Vrije Universiteit Brussel | Generation of pancreatic progenitor cells |
CN101580816B (zh) | 2009-04-23 | 2012-02-29 | 中国科学院广州生物医药与健康研究院 | 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法 |
US20120058507A1 (en) * | 2009-05-15 | 2012-03-08 | Sru Biosystems, Inc. | Clonal Derivation and Cell Culture quality Control Screening Methods |
EP4364797A3 (en) | 2009-10-19 | 2024-07-10 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte production |
ES2619564T3 (es) | 2009-11-05 | 2017-06-26 | Riken | Un método de inducción de diferenciación de células madre cultivadas |
JP6276918B2 (ja) | 2009-11-12 | 2018-02-07 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法 |
FI20096288A0 (fi) | 2009-12-04 | 2009-12-04 | Kristiina Rajala | Formulations and methods for culturing stem cells |
CA2784415C (en) | 2009-12-23 | 2019-06-18 | Jean Xu | Differentiation of human embryonic stem cells |
SG184440A1 (en) | 2010-04-08 | 2012-11-29 | Univ Edinburgh | Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
DK2582794T3 (en) | 2010-06-15 | 2018-05-22 | Cellular Dynamics Int Inc | GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD |
EP2582792B1 (en) | 2010-06-18 | 2018-10-31 | FUJIFILM Cellular Dynamics, Inc. | Cardiomyocyte medium with dialyzed serum |
EP2603583B1 (en) | 2010-08-13 | 2016-10-05 | Kyoto University | Method of inducing differentiation from pluripotent stem cells to germ cells |
EP3572501A1 (en) | 2010-09-07 | 2019-11-27 | Technion Research & Development Foundation Limited | Novel methods and culture media for culturing pluripotent stem cells |
WO2012135253A1 (en) | 2011-03-29 | 2012-10-04 | Geron Corporation | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
EP2732029B1 (en) | 2011-07-11 | 2019-01-16 | FUJIFILM Cellular Dynamics, Inc. | Methods for cell reprogramming and genome engineering |
WO2013010965A1 (en) | 2011-07-15 | 2013-01-24 | Universite Libre De Bruxelles | Generation of mesodermal cells from pluripotent stem cells |
DK3144319T3 (da) * | 2011-09-22 | 2019-08-05 | Ab Biolamina | Cellekultursammensætning indeholdende laminin-521 |
EP3530730B1 (en) | 2011-10-31 | 2022-07-20 | Riken | Method for culturing stem cell |
CN113817679A (zh) | 2011-11-25 | 2021-12-21 | 住友化学株式会社 | 制备视网膜组织和视网膜相关细胞的方法 |
RU2691027C2 (ru) | 2011-12-05 | 2019-06-07 | Фэктор Байосайенс Инк. | Способы и препараты для трансфекции клеток |
US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
SI2788472T1 (sl) | 2011-12-06 | 2019-04-30 | Astellas Institute For Regenerative Medicine | Način usmerjene diferencijacije, produciranja endotelijskih celic roženice |
RU2705001C2 (ru) | 2011-12-22 | 2019-11-01 | Янссен Байотек, Инк. | Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки |
EP2841563B1 (en) | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
AU2013271581B2 (en) | 2012-06-08 | 2018-08-09 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
EP3842524A1 (en) | 2012-06-08 | 2021-06-30 | Sumitomo Chemical Company, Limited | Method for producing ciliary marginal zone-like structure |
DE102012213838A1 (de) | 2012-08-03 | 2014-02-06 | Katharina Pachmann | Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit |
RU2711249C2 (ru) | 2012-11-01 | 2020-01-15 | Фэктор Байосайенс Инк. | Способы и продукты для экспрессии белков в клетках |
WO2014078414A1 (en) * | 2012-11-13 | 2014-05-22 | Joseph Wu | Chemically defined production of cardiomyocytes from pluripotent stem cells |
BR112015015701A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | diferenciação de células-tronco embrionárias humanas em células pancreáticas endócrinas com o uso de reguladores hb9 |
CA2896750A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
AU2014212230B2 (en) | 2013-02-01 | 2019-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs) |
JP6602288B2 (ja) | 2013-04-03 | 2019-11-06 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 浮遊液中で内胚葉前駆細胞を培養するための方法および組成物 |
EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
EP3008170A4 (en) | 2013-06-11 | 2016-11-09 | Harvard College | SC-CELLS AND COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
SG11201600813VA (en) | 2013-08-06 | 2016-03-30 | Riken | Method for producing anterior eye segment tissue |
CA2922079C (en) | 2013-08-23 | 2022-07-05 | Sumitomo Chemical Company, Limited | Method for producing retinal tissue and retina-related cells |
AU2014345110B2 (en) | 2013-11-11 | 2021-01-14 | Riken | Method for producing retinal pigment epithelial cells |
CN111269885A (zh) | 2013-11-22 | 2020-06-12 | 国立研究开发法人理化学研究所 | 制备端脑或其前体组织的方法 |
WO2015087614A1 (ja) | 2013-12-11 | 2015-06-18 | 住友化学株式会社 | 毛様体周縁部様構造体の製造法 |
KR102368751B1 (ko) | 2014-01-17 | 2022-03-03 | 스미또모 가가꾸 가부시끼가이샤 | 모양체 주연부 간세포의 제조 방법 |
EP4249036A3 (en) | 2014-01-31 | 2023-10-25 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
ES2939807T3 (es) | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
EP4137560A1 (en) | 2014-04-07 | 2023-02-22 | Mesoblast International Sàrl | Improved stem cell composition |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
CA2956130C (en) | 2014-07-25 | 2023-09-26 | Riken | Method for producing adenohypophysis or precursor tissue thereof |
KR102604999B1 (ko) | 2014-09-08 | 2023-11-23 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 소뇌 선구체 조직의 제조 방법 |
US9765299B2 (en) | 2014-09-10 | 2017-09-19 | Wisconsin Alumni Research Foundation | Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells |
US10047341B2 (en) | 2014-10-14 | 2018-08-14 | FUJIFILM Cellular Dynamics, Inc. | Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures |
CA2976376A1 (en) | 2015-02-13 | 2016-08-18 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
CA2975268A1 (en) | 2015-02-20 | 2016-08-25 | Wisconsin Alumni Research Foundation | Generating arterial endothelial cell populations |
WO2016139340A1 (en) | 2015-03-04 | 2016-09-09 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
CA2981234A1 (en) | 2015-03-30 | 2016-10-06 | Ajinomoto Co., Inc. | Chelated iron-containing culture medium for neural stem cells |
ES2952603T3 (es) | 2015-05-20 | 2023-11-02 | Univ California | Método para generar células dendríticas humanas para inmunoterapia |
CN114561277A (zh) | 2015-06-23 | 2022-05-31 | 得克萨斯州大学系统董事会 | 用于调理用于细胞疗法的细胞群体的方法和装置 |
EP3347457B1 (en) | 2015-09-08 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Macs-based purification of stem cell-derived retinal pigment epithelium |
WO2017044483A1 (en) | 2015-09-08 | 2017-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
US11649432B2 (en) | 2015-09-08 | 2023-05-16 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
ES2937052T3 (es) | 2015-09-16 | 2023-03-23 | T Curx Gmbh | Sistema mejorado de transposón para la administración de genes |
CN108463548B (zh) | 2015-10-30 | 2023-04-18 | 加利福尼亚大学董事会 | 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法 |
CN108779435B (zh) | 2015-12-07 | 2022-05-03 | 再生疗法有限公司 | 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法 |
EP3397753B1 (en) | 2015-12-30 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Microtissue formation using stem cell-derived human hepatocytes |
JP6981403B2 (ja) | 2016-03-31 | 2021-12-15 | 味の素株式会社 | 神経分化能を亢進させる神経幹細胞用培地 |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
JPWO2017188082A1 (ja) * | 2016-04-27 | 2019-02-28 | 味の素株式会社 | 培地添加剤 |
WO2017196175A1 (en) | 2016-05-12 | 2017-11-16 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium. |
KR102487142B1 (ko) | 2016-08-16 | 2023-01-12 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 만능 세포를 분화시키는 방법 |
US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
US11072780B2 (en) | 2016-09-30 | 2021-07-27 | Wisconsin Alumni Research Foundation | Method of differentiating human pluripotent cells into cardiac fibroblasts |
CN110573610A (zh) | 2017-03-08 | 2019-12-13 | 大日本住友制药株式会社 | 视网膜色素上皮细胞的制备方法 |
CN106754657B (zh) * | 2017-03-28 | 2022-07-22 | 北京赛斯达生物技术有限公司 | 一种猴胚胎干细胞的无血清培养基 |
EP3604503A4 (en) | 2017-03-28 | 2020-12-30 | Ajinomoto Co., Inc. | ADDITIVE FOR DE-DIFFERENTIATION SUPPORT MEDIUM |
JPWO2018193949A1 (ja) | 2017-04-19 | 2020-02-27 | 国立大学法人名古屋大学 | ドパミン神経細胞の調製方法 |
US11572541B2 (en) | 2017-06-09 | 2023-02-07 | Providence Health & Services—Oregon | Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer |
EP3760728B1 (en) | 2018-02-28 | 2023-11-29 | National University Corporation Tokai National Higher Education and Research System | Evaluation of cells using directional movement ability. |
KR20210005111A (ko) | 2018-04-20 | 2021-01-13 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 안구 세포의 분화를 위한 방법 및 이의 용도 |
CN112930114B (zh) | 2018-09-20 | 2023-10-03 | 艾欧凡斯生物治疗公司 | 由冷冻保存的肿瘤样品扩增til |
WO2020090903A1 (ja) | 2018-10-31 | 2020-05-07 | 国立大学法人京都大学 | 中内胚葉系への分化抵抗性が解除された多能性幹細胞の作製方法 |
AU2019374761A1 (en) | 2018-11-05 | 2021-06-10 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2022512899A (ja) | 2018-11-05 | 2022-02-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 抗pd-1抗体に対して不応性のnsclc患者の治療 |
TW202039829A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 改善之腫瘤反應性t細胞的選擇 |
JP7410518B2 (ja) | 2018-11-15 | 2024-01-10 | Jsr株式会社 | 脳オルガノイドの製造方法 |
KR20210095885A (ko) | 2018-11-19 | 2021-08-03 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 생분해성 조직 대체 임플란트 및 그의 용도 |
US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
WO2020130068A1 (ja) | 2018-12-20 | 2020-06-25 | 住友化学株式会社 | 胚型赤芽球を含む細胞集団及びその製造方法、細胞培養組成物並びに化合物試験法 |
CN114144514A (zh) | 2019-05-09 | 2022-03-04 | 富士胶片细胞动力公司 | 产生肝细胞的方法 |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US20220411759A1 (en) | 2019-05-21 | 2022-12-29 | President And Fellows Of Harvard College | Endocrine differentiation-inducing molecule |
JP2022533745A (ja) | 2019-05-22 | 2022-07-25 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | ヒト多能性細胞を培養する方法 |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
EP4008773A4 (en) * | 2019-08-03 | 2023-08-09 | Shenzhen Mytang Biotechnology Co., Ltd. | POULTRY EGG CULTURE MEDIUM |
WO2021045217A1 (ja) | 2019-09-06 | 2021-03-11 | 学校法人慶應義塾 | グリア前駆細胞を含む細胞凝集体の製造方法 |
CN110628697A (zh) * | 2019-09-23 | 2019-12-31 | 山东甲骨文生物科技有限公司 | 一种用于vero无血清细胞培养及相应病毒生产的无血清培养基 |
CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
CA3178695A1 (en) | 2020-03-31 | 2021-10-07 | Fujita Academy | Method for separating pituitary hormone-producing cells and progenitor cells thereof |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
US20230172987A1 (en) | 2020-05-04 | 2023-06-08 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2023524108A (ja) | 2020-05-04 | 2023-06-08 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 改良された腫瘍反応性t細胞の選択 |
WO2021243256A1 (en) | 2020-05-29 | 2021-12-02 | FUJIFILM Cellular Dynamics, Inc. | Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof |
MX2022015002A (es) | 2020-05-29 | 2023-03-03 | Fujifilm Cellular Dynamics Inc | Bicapa del epitelio pigmentario de la retina y fotorreceptores y uso de los mismos. |
EP3945133A1 (en) | 2020-07-29 | 2022-02-02 | Georg-August-Universität Göttingen | Mass production of human pluripotent stem cell derived cardiac stromal cell |
CN116323917A (zh) | 2020-08-18 | 2023-06-23 | 国立大学法人京都大学 | 人原始生殖细胞/人原始生殖细胞样细胞的维持扩增方法 |
US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
EP4262811A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
WO2022147196A2 (en) | 2020-12-31 | 2022-07-07 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
WO2022175815A1 (en) | 2021-02-19 | 2022-08-25 | Pfizer Inc. | Methods of protecting rna |
AR126323A1 (es) | 2021-03-05 | 2023-10-04 | Iovance Biotherapeutics Inc | Composiciones para el almacenamiento de tumores y cultivos celulares |
TW202304480A (zh) | 2021-03-19 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法 |
US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
WO2022216911A1 (en) | 2021-04-07 | 2022-10-13 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
KR20240004504A (ko) | 2021-04-11 | 2024-01-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 심근세포 및 이를 생산하기 위한 조성물 및 방법 |
AU2022263418A1 (en) | 2021-04-19 | 2023-10-26 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
EP4331673A1 (en) | 2021-04-30 | 2024-03-06 | Riken | Cord-like aggregates of retinal pigment epithelial cells, device and production method for producing same, and therapeutic agent comprising said cord-like aggregates |
US20240191186A1 (en) | 2021-05-05 | 2024-06-13 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for ipsc-derived microglia |
EP4334436A1 (en) | 2021-05-06 | 2024-03-13 | Yeda Research and Development Co. Ltd | Method for inducing hypertrophic muscle fibers for industrial meat production |
EP4340850A1 (en) | 2021-05-17 | 2024-03-27 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
JP2024520413A (ja) | 2021-05-26 | 2024-05-24 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 多能性幹細胞における遺伝子の迅速なサイレンシングを防止するための方法 |
WO2022251477A1 (en) | 2021-05-28 | 2022-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells |
AU2022280062A1 (en) | 2021-05-28 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
AU2022288058A1 (en) | 2021-06-07 | 2023-11-16 | Agonox, Inc. | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
IL309344A (en) | 2021-06-17 | 2024-02-01 | Univ Kyoto | A method for producing the preparation of cortical cells derived from human pluripotent stem cells |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
EP4398915A1 (en) | 2021-09-09 | 2024-07-17 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
KR20240055838A (ko) | 2021-09-10 | 2024-04-29 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 유도된 만능 줄기 세포 유래된 세포의 조성물 및 이의 사용 방법 |
CN118159646A (zh) | 2021-09-13 | 2024-06-07 | 富士胶片细胞动力公司 | 产生定向心脏祖细胞的方法 |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
CN118043448A (zh) | 2021-09-28 | 2024-05-14 | 学校法人藤田学园 | 使用细胞表面标记物的垂体细胞和下丘脑细胞的分离方法 |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
US20240034992A1 (en) | 2021-10-29 | 2024-02-01 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic neurons comprising mutations and methods of use thereof |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
WO2023144779A1 (en) | 2022-01-28 | 2023-08-03 | Pfizer Inc. | Coronavirus antigen variants |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
US20240003871A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Cellular Dynamics, Inc. | Ipsc-derived astrocytes and methods of use thereof |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
WO2024073759A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Apparatus and methods for delivery of cell compositions |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024137677A1 (en) | 2022-12-19 | 2024-06-27 | FUJIFILM Holdings America Corporation | Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof |
CN116574683B (zh) * | 2023-07-12 | 2023-09-29 | 中国农业大学 | 一种细胞生长促进剂及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767704A (en) * | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US5128259A (en) * | 1989-10-27 | 1992-07-07 | Hahnemann University | Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation |
NZ243160A (en) * | 1991-06-17 | 1995-03-28 | Life Technologies Inc | Preparation of cell culture media by subgrouping the ingredients into concentrated compatible formulations |
AU2882992A (en) * | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
US5332672A (en) * | 1991-12-02 | 1994-07-26 | Regeneron Pharmaceuticals, Inc. | Prevention of ES cell differentiation by ciliary neurotrophic factor |
US5453357A (en) * | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5405772A (en) * | 1993-06-18 | 1995-04-11 | Amgen Inc. | Medium for long-term proliferation and development of cells |
US5599705A (en) * | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
JP3880795B2 (ja) * | 1997-10-23 | 2007-02-14 | ジェロン・コーポレーション | フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法 |
-
1998
- 1998-01-09 AU AU57349/98A patent/AU5734998A/en not_active Abandoned
- 1998-01-09 WO PCT/US1998/000467 patent/WO1998030679A1/en active Application Filing
- 1998-01-09 EP EP98901221A patent/EP0986635A4/en not_active Ceased
- 1998-01-09 CA CA002277278A patent/CA2277278A1/en not_active Abandoned
- 1998-01-09 JP JP53115898A patent/JP2001508302A/ja not_active Ceased
-
1999
- 1999-09-07 US US09/390,634 patent/US20020076747A1/en not_active Abandoned
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4657108B2 (ja) * | 2003-12-26 | 2011-03-23 | 美保 古江 | Es細胞培養用基礎培地 |
JPWO2005063968A1 (ja) * | 2003-12-26 | 2007-07-19 | 美保 古江 | Es細胞培養用基礎培地 |
WO2005063968A1 (ja) * | 2003-12-26 | 2005-07-14 | Gs Platz Co Ltd | Es細胞培養用基礎培地 |
WO2005078070A1 (ja) * | 2004-02-13 | 2005-08-25 | Reprocell, Inc. | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 |
JPWO2005078070A1 (ja) * | 2004-02-13 | 2007-10-18 | 株式会社リプロセル | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 |
CN1298843C (zh) * | 2005-02-07 | 2007-02-07 | 十堰市太和医院 | 不依赖饲养细胞的人胚干细胞培养基 |
JP2009528034A (ja) * | 2006-02-23 | 2009-08-06 | ノヴォセル インコーポレイテッド | 分化可能細胞の培養に有用な組成物及び方法 |
JP2011500024A (ja) * | 2007-10-12 | 2011-01-06 | アドバンスド セル テクノロジー, インコーポレイテッド | Rpe細胞を生成する改良された方法およびrpe細胞の組成物 |
JP2014168482A (ja) * | 2007-10-12 | 2014-09-18 | Advanced Cell Technology Inc | Rpe細胞を生成する改良された方法およびrpe細胞の組成物 |
JP2017136088A (ja) * | 2007-10-12 | 2017-08-10 | アステラス インスティテュート フォー リジェネレイティブ メディシン | Rpe細胞を生成する改良された方法およびrpe細胞の組成物 |
US10485829B2 (en) | 2009-11-17 | 2019-11-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
US11850261B2 (en) | 2009-11-17 | 2023-12-26 | Astellas Institute For Regenerative Medicine | Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells |
EP3868873A1 (en) | 2014-10-24 | 2021-08-25 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for retinal tissue |
WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
WO2019017492A1 (ja) | 2017-07-20 | 2019-01-24 | 国立研究開発法人理化学研究所 | 連続的な上皮を含む網膜組織の成熟化方法 |
WO2019054514A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 網膜組織の製造方法 |
WO2019054515A1 (ja) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法 |
WO2019103125A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 神経系細胞又は神経組織と非神経上皮組織とを含む細胞塊の製造方法及びその細胞塊 |
WO2019103129A1 (ja) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | 下垂体組織を含む細胞塊の製造方法及びその細胞塊 |
WO2019160148A1 (ja) | 2018-02-19 | 2019-08-22 | 大日本住友製薬株式会社 | 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 |
WO2019245073A1 (ko) * | 2018-06-20 | 2019-12-26 | 주식회사 디오스템스 | 항산화 조성물 |
WO2020039732A1 (ja) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | 嗅神経細胞又はその前駆細胞を含む細胞塊、及びその製造方法 |
WO2021235377A1 (ja) * | 2020-05-18 | 2021-11-25 | 株式会社マイオリッジ | 目的細胞の生産方法、目的細胞による生産物の生産方法、および無血清培地 |
WO2023054396A1 (ja) | 2021-09-30 | 2023-04-06 | 住友化学株式会社 | 下垂体組織を含む細胞集団の製造方法及びその細胞集団 |
WO2023054395A1 (ja) | 2021-09-30 | 2023-04-06 | 住友ファーマ株式会社 | 下垂体ホルモン産生細胞を含む細胞凝集体及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0986635A1 (en) | 2000-03-22 |
US20020076747A1 (en) | 2002-06-20 |
AU5734998A (en) | 1998-08-03 |
CA2277278A1 (en) | 1998-07-16 |
EP0986635A4 (en) | 2001-11-07 |
WO1998030679A1 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001508302A (ja) | 胚性幹細胞血清置換 | |
AU623922B2 (en) | In vitro propagation of embryonic stem cells | |
JP2006288407A (ja) | 造血細胞培養栄養補充成分 | |
US8993323B2 (en) | Compositions for the in vitro derivation and culture of embryonic stem (ES) cell lines with germline transmission capability and for the culture of adult stem cells | |
WO1997025413A1 (en) | Ungulate embryonic stem-like cells, making and using the cells to produce a transgenic ungulate | |
US20120164729A1 (en) | Composition for culturing pluripotent stem cells and use thereof | |
JP4374419B2 (ja) | 多能性幹細胞培養用の組成物とその使用 | |
EP3436568B1 (en) | Culture medium for pluripotent stem cells | |
WO2021049613A1 (ja) | 未成熟卵母細胞の誘導方法及び成熟卵母細胞の作製方法 | |
AU721375B2 (en) | Porcine embryonic stem-like cells, methods of making and using the cells to produce transgenic pigs | |
JP4226598B2 (ja) | 精子幹細胞の生体外における増殖方法、その方法を利用して増殖された精子幹細胞、および精子幹細胞の生体外増殖に用いられる培地添加剤キット | |
US6180404B1 (en) | Cultural medium for maintaining neural cells in ambient atmosphere | |
JP2003520047A (ja) | 評価方法 | |
JP7173007B2 (ja) | リボフラビン誘導体含有培地 | |
US20050244960A1 (en) | Preparation of type II pneumocytes from stem cells | |
Ellen et al. | Is there a clinical future for spermatogonial stem cells? | |
CN114276984A (zh) | 雌性生殖干细胞转分化至功能精子的方法及应用 | |
JP2008104401A (ja) | 精原幹細胞のインビトロ増殖方法 | |
Kitiyanant et al. | Establishment and long-term maintenance of bovine embryonic stem cell lines using mouse and bovine mixed feeder cells and their survival after cryopreservation | |
US20050059145A1 (en) | Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells | |
JPH05304951A (ja) | 初期胚及び胚性幹細胞の培養液 | |
JPH0638742A (ja) | 動物胚幹細胞の培養方法 | |
ISHIKAWA et al. | Production of Medaka chimeras from in vitro cultured embryonic cells | |
JPWO2006028278A1 (ja) | 雄性生殖系列幹細胞のインビトロでの増殖方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050105 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070706 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080415 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080711 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080818 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080910 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081020 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090127 |